Skip to the main content.

Cell and Gene Therapy Series. Part 4 - Managing costs and scale-up risks for medical devices

Dr. Dave Seaward : 28 February 2022

Cell and Gene Therapy Series. Part 4 - Managing costs and scale-up risks for medical devices

As we continue to explore the world of cell and gene therapy, we now take a look at managing costs and scale up risks for medical devices.

Author Dave Seward, discusses how the principles of Quality by Design (QbD) and Design for Manufacture (DfM) can be applicable to ATMPs. Read this blog now!
How our robotic isolator technology is setting a new standard for aseptic fill-finish

How our robotic isolator technology is setting a new standard for aseptic fill-finish

David Johnson: 15 April 2026

In the world of pharmaceutical manufacturing, our robotic isolator technology sets a new standard for aseptic fill-finish technology. By integrating...

Read More
Key Factors to Consider During the Design Process in Aseptic Manufacturing

Key Factors to Consider During the Design Process in Aseptic Manufacturing

David Johnson: 13 April 2026

Demand for the design and development of specialist aseptic manufacturing solutions is being driven by the significant growth in biological drug...

Read More
How patent expirations will reshape the Dry Powder Inhaler (DPI) Market?

How patent expirations will reshape the Dry Powder Inhaler (DPI) Market?

Tom Bailey: 13 April 2026

Over the next few years, a wave of patent expirations for leading inhaled therapies will fundamentally change the Dry Powder Inhaler (DPI) market....

Read More